CATrends: Deceptive Deals
The holiday shopping season is here. Tread carefully.
Ozempic, Wegovy, and Other GLP-1 RA Medications
Multiple class-action lawsuits regarding the marketing of GLP-1 RAs were transferred to be heard together as part of multidistrict litigation (MDL). More information on the MDL is below.
Case Name (Date)
In Re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation
24-md-3094, E.D. Penn.
(2024)
Product/Service
Ozempic, Wegovy, Rybelsus, Saxenda, Victoza, Mounjaro, Zepbound, Trulicity and other GLP-1 RA medications
Allegations
Marketing products as weight-loss medications without adequately disclosing that many people stop using them due to their side effects, the medications do not result in meaningful weight loss for up to 15 percent of people, the average weight loss is approximately 10 percent of a person’s body weight, and people need to stay on them to maintain their weight loss
Status
Pending
The Latest
Skull Shaver’s Early Bird Sale
Trying to take advantage of this sale may not be as smooth as advertised.
Roblox Bid for Ad Riches Collides With Wary Sponsors, Developers
Cecilia D’Anastasio, Bloomberg
UIC Aspire Grant
TINA.org digs into school’s debt-free claims.
TINA.org Joins Consumer Advocates to Keep FTC Bipartisan
Why agency independence is in the best interests of consumers.